

# Jefferies 2014 Global Healthcare Conference

June 4, 2014

Linda Tharby, Group President Tom Polen, Group President



#### **Forward-Looking Statements**

 These materials include forward-looking statements and it's possible that actual results could differ from our expectations. Factors that could cause such differences appear in our second quarter earnings release and in our recent SEC filings.

#### **Non-GAAP Financial Measures**

These materials also include Non-GAAP financial measures. A reconciliation to the comparable GAAP
measures can be found in our second quarter fiscal year 2014 earnings release, the financial schedules
attached thereto and the related earnings call slides, all of which are posted on the "Investors" section of the
BD.com website.



## **Topics for Discussion**

- BD Overview and Strategic Focus
- Business Review:
  - BD Biosciences Segment
  - BD Preanalytical Systems Unit
  - BD Medical Surgical Unit
  - BD Pharmaceutical Systems Unit
- Summary



## **BD Overview and Strategic Focus**



# The Focus on Four Key Priority Areas Will Enable BD's Strategy to Drive Results

## **Build on Leading Position**& Enhance Core

- Building capabilities in emerging markets
- Rapid expansion

#### **Move into Adjacencies**

- Building more complete solutions for our customers
- Expanding addressable opportunities

# **Priority Areas**

## Reallocation of R&D Spending

- Increased spending on new product development
- Less spending on line extensions

#### **Plug-in Acquisitions**

- Accelerate moves into adjacent opportunities
- Continue to drive accelerated growth above the Company average



# Our Vision and the Changing Needs of our Customers

We are transitioning from a product focused company to a customer focused provider of healthcare solutions based on a rigorous innovation process and culture

- Improving patient outcomes and quality of care
- Lowering the cost of healthcare delivery
- Increasing healthcare access
- Optimizing patient and employee safety



**Delivering Effective Solutions for Sustainable Healthcare** 



# BDX Offers a Balanced and Diversified Portfolio

#### **Each Segment is Strongly Positioned Among Industry Peers**

## Biosciences - \$1.1B Revenue Cell Analysis, Advanced Bioprocessing **Diagnostics - \$2.6B** Revenue Preanalytical Systems \$1.4B Diagnostic Systems \$1.3B Medical - \$4.3B Revenue Medical Surgical Systems \$2.2B Diabetes Care \$1.0B Pharmaceutical Systems \$1.1B



# Focus on: BD Biosciences Segment and Preanalytical Systems Unit



## **BD Biosciences Segment**

#### **Key Product Platforms**

- Cell sorters and cell analyzers, for high and low end markets
- Clinical and research reagents
- Sirigen dyes
- **Advanced Bioprocessing**

#### **Customers Served**

- Research and clinical **laboratories**
- Academic and government institutions
- Pharmaceutical and Biotech companies
- Hospitals and reference laboratories
- **Blood banks**

#### Advancing cell analysis, discovery and clinical diagnostics with research and clinical solutions





BD FACSPresto™



BD Accuri<sup>TM</sup> Analyzer



**BD Sirigen Dyes** 



BD FACSAria<sup>TM</sup> Fusion Cell Sorter



## **BD Preanalytical Systems Unit**

#### **Key Product Platforms**

- Blood collection tubes
- Sharps, needles and wing sets
- Urine collection devices

#### **Customers Served**

- Hospitals, laboratories and clinics
- Reference laboratories
- Industrial laboratories
- Blood banks
- Public health agencies
- Physicians' office practices

# B Vocation B Constitute B Co

BD Vacutainer<sup>™</sup>
Blood Collection
Tubes

# Improving the safety and operational efficiency of clinical laboratories





BD Vacutainer<sup>TM</sup> Push Button Blood Collection Set



BD laboratory strengthening programs in emerging markets



# Focus on: BD Medical Surgical and Pharmaceutical Systems Units



## **BD Medical Surgical Unit**

#### **Key Product Platforms**

- IV catheters
- Hypodermic needles and syringes
- Prefilled flush syringes
- Hazardous drug handling solutions (BD PhaSeal<sup>TM</sup>)
- Generic prefilled syringes (BD Simplist<sup>TM</sup>)
- Medication management and workflow solutions (BD Cato<sup>TM</sup>)

# Enabling safer, simpler, and more effective parenteral drug delivery, focused on medication assurance



BD Cato<sup>™</sup> Software



#### **Customers Served**

- Hospitals and clinics
- Physicians' office practices
- Governmental and nonprofit public health agencies
- Healthcare workers



 $\mathsf{BD}\;\mathsf{Emerald}^{\mathsf{TM}}$ 

BD PhaSeal<sup>TM</sup>



BD Eclipse™ Needle and Syringe



### **BD Pharmaceutical Systems Unit**

#### **Key Product Platforms**

- Glass and Plastic Prefillable Syringes
- Prefilled Safety (SSI)
- Self Administration Systems (SAIS)

#### **Customers Served**

- Pharmaceutical and Biotech companies, products used in:
  - Acute Care
  - Chronic Diseases
  - Vaccines
  - Other

# Transforming Drug Delivery with Innovative Device Platforms





BD Hypak™





## **Summary**



- Our strategy for growth and innovation is delivering results
- Focus on complete solutions to meet customer needs and improve clinical outcomes
- Many growth opportunities to address today's most pressing healthcare challenges
- We have built a strong platform for future growth for FY 2014 and beyond
- Committed to driving value for our customers and shareholders

#### **Driving Value with Complete Solutions**



